Relationship between the benefits of suplatast tosilate, a Th2 cytokine inhibitor, and gene polymorphisms in children with bronchial asthma

Matsui,Eiko; Shinoda,Shinji; Fukutomi,Osamu; Kaneko,Hideo; Fukao,Toshiyuki; Kondo,Naomi

doi:10.3892/etm.2010.149

Relationship between the benefits of suplatast tosilate, a Th2 cytokine inhibitor, and gene polymorphisms in children with bronchial asthma

Authors:
- Eiko Matsui
- Shinji Shinoda
- Osamu Fukutomi
- Hideo Kaneko
- Toshiyuki Fukao
- Naomi Kondo
View Affiliations

Affiliations: Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan
Published online on: September 15, 2010 https://doi.org/10.3892/etm.2010.149
Pages: 977-982

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although currently available antiasthmatic drugs are effective for many patients with bronchial asthma, some patients do not respond well to medications or exhibit more frequent adverse effects compared to other patients. Antiasthmatic treatment should be tailored individually according to the predispositions and pathophysiological conditions of patients. No reports have been made concerning the relationships between the effects of Th2 cytokine inhibitors and gene polymorphisms. The present study was therefore performed to investigate the relationships between gene polymorphisms known to be involved in allergy and cytokine production in peripheral blood mononuclear cells and the clinical efficacy of suplatast tosilate, a Th2 cytokine inhibitor, to clarify factors determining responses to treatment. A total of 20 children were enrolled in the study. The children were enrolled in a run-in period of 2 weeks and then received suplatast tosilate orally for 8 weeks. The children or their parents were instructed to keep an asthma diary to record changes in signs/symptoms of bronchial asthma before and after treatment. Concentrations of interferon (IFN)-γ and interleukin (IL)-4 in the supernatant were determined using ELISA methods. Using the invader assay method, the genotypes of polymorphisms of the genes were determined. Treatment with suplatast tosilate was more effective in children without the -444 A/C polymorphism of the LTC4 synthase gene and in children without the IL-13 variant R110Q. In children who responded well, production of IFN-γ was significantly increased after treatment. In this study, responses to suplatast tosilate were associated with SNPs of the LTC4 synthase and IL-13 gene as well as change in the production of IFN-γ before and after drug administration.

View Figures

View References

1.	Kondo N, Matsui E, Kaneko H, Kato Z, Fukao T, Teramoto T, Shikano H, Aoki M, Onishi H, Tatebayashi K, Omoya K, Kondo M, Matsukuma E, Kasahara K and Morimoto N: Genetic defects in downregulation of IgE production and a new genetic classification of atopy. Allergol Int. 53:77–85. 2004. View Article : Google Scholar
2.	Mitsuyasu H, Izuhara K, Mao XQ, Gao PS, Arinobu Y, Enomoto T, Kawai M, Sasaki S, Dake Y, Hamasaki N, Shirakawa T and Hopkin JM: Ile50Val variant of IL4R alpha upregulates IgE synthesis and associates with atopic asthma. Nat Genet. 19:119–120. 1998. View Article : Google Scholar : PubMed/NCBI
3.	Heinzmann A, Mao XQ, Akaiwa M, Kreomer RT, Gao PS, Ohshima K, Umeshita R, Abe Y, Braun S, Yamashita T, Roberts MH, Sugimoto R, Arima K, Arinobu Y, Yu B, Kruse S, Enomoto T, Dake Y, Kawai M, Shimazu S, Sasaki S, Adra CN, Kitaichi M, Inoue H, Yamauchi K, Tomichi N, Kurimoto F, Hamasaki N, Hopkin JM, Izuhara K, Shirakawa T and Deichmann KA: Genetic variants of IL-13 signalling and human asthma and atopy. Hum Mol Genet. 9:549–559. 2000. View Article : Google Scholar : PubMed/NCBI
4.	Tatebayashi K, Matsui E, Kaneko H, Fukao T, Kasahara K and Kondo N: IL-12B promoter polymorphism associated with asthma and IL-12B transcriptional activity. Allergol Int. 54:451–459. 2005. View Article : Google Scholar
5.	Yoshikawa K, Matsui E, Kaneko H, Fukao T, Inoue R, Teramoto T, Shinoda S, Fukutomi O, Aoki M, Kasahara K and Kondo N: A novel single-nucleotide substitution, Glu 4 Lys, in the leukotriene C4 synthase gene associated with allergic diseases. Int J Mol Med. 16:827–831. 2005.PubMed/NCBI
6.	Aoki M, Matsui E, Kaneko H, Inoue R, Fukao T, Watanabe M, Teramoto T, Kato Z, Suzuki K, Suzuki Y, Kasahara K and Kondo N: A novel single-nucleotide substitution, Leu 467 Pro, in the interferon-γ receptor 1 gene associated with allergic diseases. Int J Mol Med. 12:185–191. 2003.PubMed/NCBI
7.	Tan S, Hall IP, Dewar J, Dow E and Lipworth B: Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 350:995–999. 1997. View Article : Google Scholar : PubMed/NCBI
8.	Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST, Holloway JW and Sayers I: Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax. 55(Suppl 2): 28–31. 2000. View Article : Google Scholar : PubMed/NCBI
9.	Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki T, Hakuno H, Fukunaga K, Suzuki Y, Kanazawa M and Yamaguchi K: Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics. 12:565–570. 2002. View Article : Google Scholar : PubMed/NCBI
10.	Tantisira KG, Hwang ES, Raby BA, Silverman ES, Lake SL, Richter BG, Peng SL, Drazen JM, Glimcher LH and Weiss ST: TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci USA. 101:18099–18104. 2004. View Article : Google Scholar : PubMed/NCBI
11.	Hall JG, Eis PS, Law SM, Reynaldo LP, Prudent JR, Marshall DJ, Allawi HT, Mast AL, Dahlberg JE, Kwiatkowski RW, de Arruda M, Neri BP and Lyamichev VI: Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction. Proc Natl Acad Sci USA. 97:8272–8277. 2000. View Article : Google Scholar : PubMed/NCBI
12.	Shim JJ, Dabbagh K, Takeyama K, Burgel PR, Dao-Pick TP, Ueki IF and Nadel JA: Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. J Allergy Clin Immunol. 105:739–745. 2000. View Article : Google Scholar : PubMed/NCBI
13.	Suwaki T, Agrawal DK and Townley RG: Modification of eosinophil function by suplatast tosilate (IPD), a novel antiallergic drug. Int Immunopharmacol. 1:2163–2171. 2001. View Article : Google Scholar : PubMed/NCBI
14.	Espinosa K, Bossé Y, Stankova J and Rola-Pleszczynski M: CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4. J Allergy Clin Immunol. 111:1032–1040. 2003. View Article : Google Scholar : PubMed/NCBI